Maze Therapeutics, Inc.
NASDAQ:MAZEBiotechnology
+$0.18 today
- Market cap
- $1.71B
- Beta
- 2.26
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.27
Volume 0.71M
Average 0.84M
MAZE Other Working Capital
Cash effect of changes in other operating assets and liabilities.
Maze Therapeutics, Inc.NASDAQ: MAZE
Other Working Capital · Q1 FY2026 · quarter ended Mar 2026
Other working capital growth accelerates
Q1 FY2026 other working capital of $5.89M (cash outflow) rose 193.8% year over year, ahead of the +9.3% change in trailing-twelve-month other working capital.
Context
- Other working capital increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +193.8% holds above the trailing-twelve-month pace of +9.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Working Capital history
USD · from the cash flow
- Latest · FY2025
- (2.25M) USD
- Year-over-year change
- -70.3%
| Period | Period end | Other Working Capital | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (2.25M) | -70.3% |
| FY2024 | 2024-12-31 | (1.32M) | +80.4% |
| FY2023 | 2023-12-31 | (6.72M) | -1341.2% |
| FY2022 | 2022-12-31 | 541K | — |
Other Working Capital vs competitors
How MAZE compares with its peers on the latest reported figures
- Peers report in different currencies, so other working capital is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +9.3% is the 5th highest of 8, against a peer median of +109.4%.
- Other working capital amounts to 20.8% of revenue for MAZE, versus a peer median of 9.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $42.44M USD | +24575.6% | +82.5% | 6.5% | |
| LTM Mar 2026 | $15.82M USD | +109.4% | +6.8% | 3.7% | |
SEPNSepterna, Inc. | LTM Sep 2026 | $11.35M USD | -106.4% | +1926.2% | 11.8% |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $9.01M USD | -228.5% | +290.5% | 87.3% |
| LTM Jun 2026 | $8.63M USD | +169.3% | — | 0.9% | |
| LTM Mar 2026 | $4.17M USD | +9.3% | — | 20.8% | |
| FY2025 | €3.15M EUR | +303.7% | — | 70.2% | |
| LTM Mar 2026 | $675.29K USD | -130.9% | -19.6% | — | |
| Peer median (excluding MAZE) | — | +109.4% | +82.5% | 9.2% | |
Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Maze Therapeutics, Inc.
NASDAQ:MAZE
Intrinsic Alpha fair value
Locked
Current Price
$31.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.